SCHEMBL20148747

SCHEMBL20148747

Cc1ccc(S(=O)(=O)N2CC23CCN(C(C)C)CC3)cc1

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.60
LMNA P02545 1/20 0.60
KMT2A Q03164 4/20 0.47
PKM P14618 3/20 0.44
HTT P42858 2/20 0.43
ALDH1A1 P00352 1/20 0.43
POLB P06746 1/20 0.43
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 3/20 0.40
TSHR P16473 1/20 0.40
CYP2C19 P33261 1/20 0.40
MMP2 P08253 1/20 0.40
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
MDM2 Q00987 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20160470 0.89 GAA (0.47) GAALMNAKMT2APKMHTT
SCHEMBL20071377 0.87 LMNA (0.44) GAALMNAKMT2APKMHTT
SCHEMBL20148744 0.87 CYP2D6 (0.47) GAALMNAALDH1A1TSHRCYP2C19
SCHEMBL20148748 0.86 MMP1 (0.53) GAALMNAPKMHTTALDH1A1
SCHEMBL20154516 0.84 KMT2A (0.50) GAAKMT2APKMHTTALDH1A1
SCHEMBL20071375 0.82 KMT2A (0.49) GAALMNAKMT2APKMHTT
SCHEMBL12296593 0.82 KMT2A (0.54) LMNAKMT2APKMHTTALDH1A1
SCHEMBL1919732 0.80 KMT2A (0.53) LMNAKMT2APKMHTTALDH1A1
SCHEMBL20626519 0.80 KDM2B (0.51) GAAKMT2APKMHTTALDH1A1
SCHEMBL2438590 0.78 KMT2A (0.50) GAALMNAKMT2APKMHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240066029-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2024-02-29 US disclosed
US-20210186959-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA, INC. 2021-06-24 US disclosed
EP-3753939-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS Array Biopharma Inc. (US) 2020-12-23 EP disclosed
EP-3523301-B1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2020-05-27 EP disclosed
US-20180133213-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
US-20180133200-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
US-20180134702-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134702-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF GAA 3170/4885LMNA 2631/4885KMT2A 1171/4885
US-20180133200-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF GAA 3170/4885LMNA 2631/4885KMT2A 1171/4885
US-20210186959-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF GAA 3170/4885LMNA 2631/4885KMT2A 1171/4885
US-20180133213-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF GAA 3170/4885LMNA 2631/4885KMT2A 1171/4885
US-20240066029-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF GAA 3170/4885LMNA 2631/4885KMT2A 1171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.